The effect of Oleoylethanolamide supplementation on oxidative stress parameters in multiple sclerosis patients

The effect of Oleoylethanolamide (OEA) supplementation on oxidative stress parameters in multiple sclerosis patients : A randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210419051012N1

Enrollment

Registered

2021-07-08

Start date

2021-08-05

Completion date

Unknown

Last updated

2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis. Multiple sclerosis

Interventions

Intervention 1: Intervention group: Take two oleoyl ethanamide supplements (250 mg) daily orally for six weeks. Supplements are provided by Karen Company. Intervention 2: Control group: Take two place

Eligibility

Sex/Gender

All

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: MS type of relapsing_remitting MS patients are treating with beta interferon Willingness to cooperate Patients with an age range of 20 to 40 years

Exclusion criteria

Exclusion criteria: MS patients are treating with Corticosteroids Taking immunosuppressive drugs History of rheumatic and collagen and vascular diseases History of recent infections (during the last 2 to 3 months) Swallowing disorders that are unable to take medication Sensitivity to compounds No regular use of supplements Reluctance to cooperate

Design outcomes

Primary

Measure	Time frame
Red blood cell. Timepoint: Before and after the intervention. Method of measurement: laboratory.;White blood cell. Timepoint: Before and after the intervention. Method of measurement: laboratory.;Plt. Timepoint: Before and after the intervention. Method of measurement: laboratory.;Interleukin 17. Timepoint: Before and after the intervention. Method of measurement: ELISA.;TNF-a. Timepoint: Before and after the intervention. Method of measurement: ELISA.;UREA. Timepoint: Before and after the intervention. Method of measurement: Labratory.;TG. Timepoint: Before and after the intervention. Method of measurement: Laboratory.;Cholesterol. Timepoint: Before and after the intervention. Method of measurement: Laboratory.;PLT. Timepoint: Before and after the intervention. Method of measurement: Laboratory.;Total antioxidant capacity. Timepoint: Before and after the intervention. Method of measurement: Spectrophotometer.;Catalase enzyme activity. Timepoint: Before and after the intervention. Method of measurement: Spectrophotometer.;Protein oxidation. Timepoint: Before and after the intervention. Method of measurement: Spectrophotometer.	—

Measure

Time frame

Red blood cell. Timepoint: Before and after the intervention. Method of measurement: laboratory.;White blood cell. Timepoint: Before and after the intervention. Method of measurement: laboratory.;Plt. Timepoint: Before and after the intervention. Method of measurement: laboratory.;Interleukin 17. Timepoint: Before and after the intervention. Method of measurement: ELISA.;TNF-a. Timepoint: Before and after the intervention. Method of measurement: ELISA.;UREA. Timepoint: Before and after the intervention. Method of measurement: Labratory.;TG. Timepoint: Before and after the intervention. Method of measurement: Laboratory.;Cholesterol. Timepoint: Before and after the intervention. Method of measurement: Laboratory.;PLT. Timepoint: Before and after the intervention. Method of measurement: Laboratory.;Total antioxidant capacity. Timepoint: Before and after the intervention. Method of measurement: Spectrophotometer.;Catalase enzyme activity. Timepoint: Before and after the intervention. Method of measurement: Spectrophotometer.;Protein oxidation. Timepoint: Before and after the intervention. Method of measurement: Spectrophotometer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAkram Ranjbar

Hamedan University of Medical Sciences

a.ranjbar@umsha.ac.ir+98 81 3827 4191

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026